Takeda Oncology
Ian Armitage has over 25 years of experience in the pharmaceutical industry, currently serving as the Director of Pharmaceutics Research at Takeda Pharmaceuticals International Co. since December 2014, after transitioning from a role as Senior Scientist/Group Leader in Process Chemistry. Prior to this, Ian spent over five years as a Chemical Development Chemist at GSK. Ian relocated from the UK to the US facilities of Takeda in December 2003, having joined the company when it was known as Cambridge Discovery Chemistry and later Millennium Pharmaceuticals. Ian Armitage holds a degree from the University of Nottingham.
This person is not in the org chart
This person is not in any teams
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.